Oric Pharmaceuticals Inc

NASDAQ ORIC

Data sourced from iex and EODHD
Download Data

Oric Pharmaceuticals Inc Income Statement 2019 - 2024

This table shows the Income Statement for Oric Pharmaceuticals Inc going from 2019 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31
Revenue
M 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 0 0 0 0 0 0 - - - - - - - - - - - - - - -
Gross Profit
M 0 1 0 0 0 0 - - - - - - - - - - - - - - -
Operating Expenses
M 29 33 28 25 25 22 - - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 7 7 6 6 6 6 6 7 6 6 6 6 5 4 4 3 2 2 1 1 1
Research and Development (R&D) Expenses
M 22 24 22 19 20 16 15 14 17 17 13 16 12 12 9 8 7 7 6 5 5
Other Operating Expenses
M 0 1 0 0 0 0 - - - - - - - - - - - - - - -
Costs and Expenses
M 28 31 28 25 25 22 - - - - - - - - - - - - - - -
Operating Income
M -29 -31 -29 -25 -26 -22 -26 -21 -23 -23 -18 -21 -17 -28 -26 -11 -9 -9 -7 -6 -6
Interest Expense
M - 2 - - 2 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Non-operating Income/Expense
M 4 3 3 2 2 1 1 0 0 -16 0 0 0 -12 -13 0 0 0 0 0 0
EBT
M -25 -28 -25 -23 -24 -21 -25 -20 -23 -23 -18 -21 -17 -28 -26 -11 -9 -8 -7 -6 -6
Income Tax Provision
M - 2 0 - -2 -1 -1 0 0 0 0 0 0 0 0 0 -1 0 -1 0 -1
Income after Tax
M - -31 -25 - -22 -20 -24 -20 -23 -23 -18 -21 -16 -28 -26 -11 -8 -8 -6 -6 -5
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Net Income
M - - - -23 -24 -21 -25 -20 -23 -23 -18 -21 -17 -28 -26 -11 -9 - -7 -6 -6
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 67,349,551.00 57,464,041.00 57,402,226.00 45,654,208.00 45,090,166.00 40,125,286.00 39,575,660.00 39,481,628.00 39,431,722.00 39,386,166.00 39,008,114.00 36,701,836.00 36,679,684.00 33,618,477.00 30,314,904.00 21,627,361.00 27,542,407.00 19,141,209.00 19,141,209.00 19,141,209.00 19,141,209.00
EBITDA
M -29 -31 -29 -25 -26 -22 -16 -20 -23 -23 -18 -21 -16 -5 1 -11 -9 -9 -7 -6 -6
Depreciation and Amortization
M 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0
EBIT
M -29 -31 -29 -25 -26 -22 -26 -21 -23 -23 -18 -21 -17 -5 0 -11 -9 -9 -7 -6 -6
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -7.92 1.01 - 8.29 6.10 3.48 2.02 0.43 0.15 0.16 0.16 0.53 0.11 0.04 0.23 6.18 4.99 8.37 6.54 9.84
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% - 82.90 - - - - - - - - - - - - - - - - - - -
Operating Income Margin
% - -2,043.43 - - - - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -2,026.33 - - - - - - - - - - - - - - - - - - -
EBIT Ratio
% - -2,043.43 - - - - - - - - - - - - - - - - - - -
EBT Ratio
% - -1,842.00 - - - - - - - - - - - - - - - - - - -

StockViz Staff

September 19, 2024

Any question? Send us an email